Peptide therapy in Hagerstown, MD

BPC-157 and GHK-Cu when clinically appropriate. Additional therapies may be discussed after clinical review — inquire within. We do not market DIY research-chemical stacks.

Online posts often oversell recovery claims. At Kairos, BPC-157 is considered only in a supervised medical pathway after history and, when indicated, labs — not as a guaranteed healing product. Evidence has limits; we stay educational and consult-first.

GHK-Cu is a copper peptide people discuss for skin and regenerative support goals. It is not only cosmetic marketing — but it is also not a miracle. Suitability and goals are reviewed at consult under physician leadership.

No. Kairos does not supervise patient-sourced research peptides or unverified mail-order products. Clinic pathways use medically appropriate sourcing and follow-up inside a LegitScript-certified practice.

No. Peptides are not a substitute for physician-supervised hormone or metabolic care when those pathways are indicated. They may be sequenced alongside other plans after clinical review — never stacked randomly.

Approval status varies by product and formulation. We do not treat clinic peptides as OTC supplements. Options, limits, and regulatory context are explained at consult — without inventing approvals.

Medical evaluation, appropriate sourcing, and follow-up in a LegitScript-certified clinic — not unregulated research products sold as “for research only.”

Often discussed after clinical review — sequenced for safety, not stacked randomly. Confirm at a complimentary consult.

Some consults/follow-ups may be virtual in eligible states (MD, PA, WV, CA, FL). Specific therapies depend on clinical and regulatory factors.